Lipiodol
Updates to Article Attributes
Lipiodol® (also known as ethiodized oil) is an oil-based iodinated contrast medium that was historically used for myelography and hysterosalpingography. It was later superseded by newer, less hazardous, agents, and now is used primarily as a therapeutic agent. Guerbet is now the sole manufacturer of this agent.
Structure
Lipiodol comprises a combination of iodine and ethyl esters of poppy seed oil 6. The iodine is intercalated into the constituent fatty acids to produce a mixture of iodostearic and stearic-acid derived esters. The precise structure of Lipiodol has never been characterised 6.
Uses
Diagnostic
- hysterosalpingography
- lymphography
- dacryocystography (DCG)
-
conventional transcatheter hepatic arterial chemoembolisation (cTACE) 3
- transcatheter radioembolisation was initially developed using
Lipiodollipiodol, but now non-Lipiodol-lipiodol drug-eluted glass or resin microspheres are preferred 4,5
- transcatheter radioembolisation was initially developed using
Therapeutic
Lipiodol radiolabeledmarked with Re-188
Rhenium-188 Lipiodol188Re-Lipiodol is a radiopharmaceutical that can be used to treat patients with unresectable hepatocellular carcinoma. The final lipophilic complex, bis-(diethyldithiocarbamato) nitrido rhenium-188, to be administered through the hepatic artery, is as follows: Re-188 N188ReN (DEDC) 2-Lipiodol 7-10
History and etymology
Lipiodol was discovered by the co-founders of the healthcare company Guerbet, Marcel Guerbet and Laurent Lafay in 1901 2. Indeed originally it was marketed as Lipiodol Lafay. It was originally developed as a therapeutic agent - a way to deliver iodine to tissues.
It was first employed in radiology in 1921 by Jean-Athanase Sicard and Jacques Forestier, French radiologists, who developed positive contrast myelography. This supplanted air myelography which had been used until then. Due to complications (e.g. chemical arachnoiditis) Lipiodol was itself superseded by iophendylate.
It was previously marketed as Ethiodol® in the US, but is now globally sold as Lipiodol.
-<p><strong>Lipiodol<sup>®</sup></strong> (also known as <strong>ethiodized oil</strong>) is an oil-based <a href="/articles/iodinated-contrast-media-1">iodinated contrast medium</a> that was historically used for <a href="/articles/myelography">myelography</a> and <a href="/articles/hysterosalpingogram">hysterosalpingography</a>. It was later superseded by newer, less hazardous, agents, and now is used primarily as a therapeutic agent. <a href="/articles/guerbet">Guerbet</a> is now the sole manufacturer of this agent.</p><h4>Structure</h4><p>Lipiodol comprises a combination of iodine and ethyl esters of poppy seed oil <sup>6</sup>. The iodine is intercalated into the constituent fatty acids to produce a mixture of iodostearic and stearic-acid derived esters. The precise structure of Lipiodol has never been characterised <sup>6</sup>.</p><h4>Uses</h4><h5>Diagnostic</h5><ul>- +<p><strong>Lipiodol<sup>®</sup></strong> (also known as <strong>ethiodized oil</strong>) is an oil-based <a href="/articles/iodinated-contrast-media-1">iodinated contrast medium</a> that was historically used for <a href="/articles/myelography">myelography</a> and <a href="/articles/hysterosalpingogram">hysterosalpingography</a>. It was later superseded by newer, less hazardous, agents, and now is used primarily as a therapeutic agent. <a href="/articles/guerbet">Guerbet</a> is now the sole manufacturer of this agent.</p><h4>Structure</h4><p>Lipiodol comprises a combination of iodine and ethyl esters of poppy seed oil <sup>6</sup>. The iodine is intercalated into the constituent fatty acids to produce a mixture of iodostearic and stearic-acid derived esters. The precise structure of Lipiodol has never been characterised <sup>6</sup>.</p><h4>Uses</h4><ul>
-<a href="/articles/transcatheter-arterial-chemoembolisation">conventional transcatheter hepatic arterial chemoembolisation (cTACE)</a> <sup>3</sup><ul><li>transcatheter radioembolisation was initially developed using Lipiodol, but now non-Lipiodol drug-eluted glass or resin microspheres are preferred <sup>4,5</sup>- +<a href="/articles/transcatheter-arterial-chemoembolisation">conventional transcatheter hepatic arterial chemoembolisation (cTACE)</a> <sup>3</sup><ul><li>transcatheter radioembolisation was initially developed using lipiodol, but now non-lipiodol drug-eluted glass or resin microspheres are preferred <sup>4,5</sup>
-</ul><h5>Therapeutic</h5><h6>Lipiodol radiolabeled with Re-188</h6><p>Rhenium-188 Lipiodol is a radiopharmaceutical that can be used to treat patients with unresectable hepatocellular carcinoma. The final lipophilic complex, bis-(diethyldithiocarbamato) nitrido rhenium-188, to be administered through the hepatic artery, is as follows: Re-188 N (DEDC)<sub> 2</sub>-Lipiodol<sup> 7-10</sup>.</p><h4>History and etymology</h4><p>Lipiodol was discovered by the co-founders of the healthcare company Guerbet, <strong>Marcel Guerbet</strong> and <strong>Laurent Lafay</strong> in 1901 <sup>2</sup>. Indeed originally it was marketed as <strong>Lipiodol Lafay.</strong> It was originally developed as a therapeutic agent - a way to deliver iodine to tissues.</p><p>It was first employed in radiology in 1921 by <strong>Jean-Athanase Sicard</strong> and <strong>Jacques Forestier</strong>, French radiologists, who developed positive contrast myelography. This supplanted air myelography which had been used until then. Due to complications (e.g. chemical <a href="/articles/arachnoiditis">arachnoiditis</a>) Lipiodol was itself superseded by <a href="/articles/iophendylate">iophendylate</a>.</p><p>It was previously marketed as Ethiodol<sup>®</sup> in the US, but is now globally sold as Lipiodol. </p>- +</ul><h5> </h5><h5>Lipiodol marked with Re-188</h5><p><sup>188</sup>Re-Lipiodol is a radiopharmaceutical that can be used to treat patients with hepatocellular carcinoma. The final lipophilic complex, to be administered through the hepatic artery, is as follows: <sup>188</sup>ReN (DEDC)<sub> 2</sub>-Lipiodol (bis-diethyldithiocarbamate nitride rhenium-188).</p><p> </p><h4>History and etymology</h4><p>Lipiodol was discovered by the co-founders of the healthcare company Guerbet, <strong>Marcel Guerbet</strong> and <strong>Laurent Lafay</strong> in 1901 <sup>2</sup>. Indeed originally it was marketed as <strong>Lipiodol Lafay.</strong> It was originally developed as a therapeutic agent - a way to deliver iodine to tissues.</p><p>It was first employed in radiology in 1921 by <strong>Jean-Athanase Sicard</strong> and <strong>Jacques Forestier</strong>, French radiologists, who developed positive contrast myelography. This supplanted air myelography which had been used until then. Due to complications (e.g. chemical <a href="/articles/arachnoiditis">arachnoiditis</a>) Lipiodol was itself superseded by <a href="/articles/iophendylate">iophendylate</a>.</p><p>It was previously marketed as <strong>Ethiodol<sup>®</sup></strong> in the US, but is now globally sold as Lipiodol. </p>